Despite having seven employees who all work from home, FerroKin Biosciences plans to bring a drug to market in 2015, reports The Atlantic's Quinn Norton. This low overhead model, Norton adds, allows the companies to focus on nice drugs, and the one FerroKin is developing is to treat congenital anemias.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.